11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF

Emergency Triage of Critical Tachyarrhythmias

Tachyarrhythmias (heart rate $> 100\text{ bpm}$, typically clinically significant when $> 150\text{ bpm}$) frequently precipitate or accelerate cardiorespiratory failure in the intensive care unit. The initial evaluation requires immediate parallel assessment of hemodynamic stability, QRS complex duration (narrow $< 120\text{ ms}$ vs. wide $\ge 120\text{ ms}$), and rhythm regularity.

Hemodynamic Instability and Electrical Cardioversion

A patient is classified as hemodynamically unstable when the tachyarrhythmia produces any of the following four critical manifestations:

1. Systemic Hypotension / Shock: Mean arterial pressure $< 65\text{ mmHg}$, systolic blood pressure $< 90\text{ mmHg}$, or clinical signs of hypoperfusion (cool clammy extremities, oliguria, worsening lactic acidosis).
2. Acute Altered Mental Status: Agitation, confusion, lethargy, or syncope resulting from cerebral hypoperfusion.
3. Ischemic Chest Discomfort: Ongoing angina or ECG evidence of acute myocardial ischemia (ST elevations or horizontal/downsloping ST depressions).
4. Acute Pulmonary Edema: Flash pulmonary congestion with respiratory distress, rales, and hypoxemia.

                  TACHYARRHYTHMIA ASSESSMENT (HR > 150 BPM)
                                     │
                 ┌───────────────────┴───────────────────┐
                 ▼                                       ▼
        UNSTABLE PATIENT                         STABLE PATIENT
  • Hypotension / Shock                   • Differentiate QRS width:
  • Altered mental status                   - Narrow (< 120 ms)
  • Ischemic chest pain                     - Wide (>= 120 ms)
  • Flash pulmonary edema                 • Regular vs. Irregular
                 │                                       │
                 ▼                                       ▼
     IMMEDIATE SYNCHRONIZED                    TARGETED PHARMACOTHERAPY
      CARDIOVERSION (Biphasic)                 • AF/Flutter: Esmolol, Diltiazem,
  • AF: 120-200 J                                Amiodarone
  • Flutter / PSVT: 50-100 J                   • Monomorphic VT: Procainamide,
  • Monomorphic VT: 100 J                        Amiodarone
  • Pulseless VT / VF:                         • Torsades de Pointes: IV MgSO4,
    UNSYNCHRONIZED DEFIBRILLATION                Overdrive pacing, Isoproterenol

Synchronized Electrical Cardioversion Technique

For any unstable tachyarrhythmia with a pulse, immediate synchronized electrical cardioversion is mandatory:

• Synchronization Mechanism: The defibrillator detects the peak of the intrinsic R-wave of the QRS complex and delivers energy exclusively during ventricular depolarization. This avoids delivering an electrical shock during the vulnerable period of repolarization (the upslope and peak of the T-wave), preventing the catastrophic R-on-T phenomenon that induces refractory ventricular fibrillation.
• Recommended Energy Levels (Biphasic):
  • Atrial Fibrillation: $120\text{--}200\text{ J}$ biphasic (or $200\text{ J}$ monophasic).
  • Atrial Flutter and Paroxysmal Supraventricular Tachycardia (PSVT): $50\text{--}100\text{ J}$ biphasic.
  • Monomorphic Ventricular Tachycardia with a pulse: $100\text{ J}$ biphasic.
• Pulseless VT and Ventricular Fibrillation (VF): In pulseless arrest, the machine cannot identify or synchronize to an R-wave. Immediate high-energy unsynchronized defibrillation ($120\text{--}200\text{ J}$ biphasic, $360\text{ J}$ monophasic) is administered immediately, followed by high-quality chest compressions and the standard ACLS cardiac arrest protocol.

---

Atrial Fibrillation with Rapid Ventricular Response (RVR)

New-onset atrial fibrillation with RVR occurs in up to $30\%$ of critically ill patients. It is characterized by chaotic, irregular fibrillatory baseline waves without discernible P waves and an irregularly irregular ventricular response, frequently exceeding $140\text{--}180\text{ bpm}$. Loss of the coordinated atrial booster pump ("atrial kick") reduces left ventricular filling by $20\%\text{ to }30\%$, which, combined with shortened diastolic filling time at high ventricular rates, precipitates acute hemodynamic deterioration.

Precipitating Triggers in the Intensive Care Unit

In the vast majority of ICU admissions, AF with RVR is a secondary manifestation of underlying physiological stress rather than an isolated primary cardiac event. Critical care clinicians must systematically evaluate for:

• Systemic Inflammation & Infection: Severe sepsis, septic shock, pneumonia, SIRS, and bacteremia.
• Electrolyte Derangements: Severe hypokalemia ($K^+ < 4.0\text{ mEq/L}$) and hypomagnesemia ($Mg^{2+} < 2.0\text{ mg/dL}$).
• Catecholamine Surges: Endogenous pain, agitation, withdrawal, or exogenous vasopressor/inotropic infusions (norepinephrine, epinephrine, dopamine).
• Intravascular Volume Shifts: Hypervolemia causing acute atrial stretch, or severe hypovolemia provoking compensatory neurohumoral activation.
• Cardiopulmonary Pathologies: Acute pulmonary embolism, severe hypoxemia, acute hypercapnic respiratory failure, pericarditis, and recent cardiothoracic surgery.

Rate Control Pharmacotherapy in the ICU

When the patient is hemodynamically stable, pharmacotherapy is titrated toward a lenient resting heart rate target of $< 110\text{ bpm}$:

1. Intravenous Beta-Adrenergic Blockers:
   • Esmolol: An ultra-short-acting, cardioselective $\beta_1$-receptor antagonist. Administer an optional loading bolus of $500\mu\text{g/kg}$ over 1 minute, followed by a continuous infusion of $50\mu\text{g/kg/min}$, titrated every 5 to 10 minutes by increments of $50\mu\text{g/kg/min}$ up to a maximum of $200\text{--}300\mu\text{g/kg/min}$.
     • ICU Advantage: Rapid onset ($< 2\text{ minutes}$) and ultra-short elimination half-life ($9\text{ minutes}$). If drug-induced hypotension or heart failure occurs, stopping the infusion results in complete hemodynamic recovery within 15 to 30 minutes.
   • Metoprolol Tartrate: $2.5\text{--}5.0\text{ mg}$ slow IV push over 2 minutes, repeated every 5 minutes up to a maximum cumulative dose of $15\text{ mg}$.
   • Contraindications: Acute decompensated heart failure with reduced ejection fraction (HFrEF), severe bronchospasm, or cardiogenic shock.
2. Non-Dihydropyridine Calcium Channel Blockers:
   • Diltiazem: Highly potent AV-nodal blocking agent. Administer an initial bolus of $0.25\text{ mg/kg}$ (typically $15\text{--}20\text{ mg}$) IV over 2 minutes; if rate response is inadequate after 15 minutes, deliver a second bolus of $0.35\text{ mg/kg}$ (typically $20\text{--}25\text{ mg}$), followed by a continuous infusion of $5\text{--}15\text{ mg/hr}$.
   • Strict Contraindications: Decompensated heart failure with reduced ejection fraction ($\text{LVEF} < 40\%$) due to potent negative inotropic properties that trigger pulmonary edema and cardiogenic shock. Strictly contraindicated in pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome), where AV nodal blockade diverts rapid impulses down the accessory pathway, degenerating into VF.
3. Intravenous Amiodarone:
   • Agent of Choice in Structural Heart Disease / HFrEF: Amiodarone is the safest and most effective agent for rate and rhythm control in patients with severe left ventricular systolic dysfunction ($\text{LVEF} < 40\%$), active myocardial ischemia, or borderline hypotension.
   • Dosing: $150\text{ mg}$ IV diluted in $100\text{ mL}$ $D_5W$ infused over 10 minutes, followed by a continuous infusion of $1.0\text{ mg/min}$ for 6 hours ($360\text{ mg}$), then $0.5\text{ mg/min}$ for 18 hours ($540\text{ mg}$); cumulative 24-hour dose $\approx 1000\text{ mg}$ (max $2.2\text{ g}$). Supplemental $150\text{ mg}$ boluses can be delivered for breakthrough tachycardias.
   • Mechanism: Possesses class III potassium-channel blocking action alongside non-competitive $\beta$-blockade, calcium-channel blockade, and sodium-channel blockade. Slows AV nodal conduction without depressing LV inotropy.
4. Intravenous Digoxin:
   • Administer $0.25\text{--}0.5\text{ mg}$ IV loading dose, followed by $0.25\text{ mg}$ every 4 to 6 hours to a maximum of $1.0\text{ mg}$ over 24 hours.
   • Clinical Role: Relies on vagomimetic parasympathetic activation to slow AV nodal conduction. In the hyperadrenergic state of the ICU (high circulating catecholamines), digoxin as monotherapy is largely ineffective for acute rate control. It is utilized primarily as a safe, non-depressant adjunct in patients with HFrEF and shock who cannot tolerate beta-blockers or calcium channel blockers.

Anticoagulation Decisions in the Intensive Care Unit

Balancing thromboembolic stroke prevention against bleeding risk in the ICU requires nuanced clinical judgment:

• Thromboembolic Risk: Assessed using the $\text{CHA}_2\text{DS}_2\text{-VASc}$ score. However, critically ill patients often possess transient, unquantified hypercoagulability (septic endothelial activation).
• Bleeding Risk: Intensive care patients frequently exhibit major bleeding risk factors: invasive lines, surgical wounds, active coagulopathy, thrombocytopenia, and acute renal failure.
• Cardioversion Safety Threshold: If new-onset AF has been continuously present for $> 48\text{ hours}$ (or if duration is unknown), elective cardioversion carries a substantial risk of dislodging a left atrial appendage (LAA) thrombus. A transesophageal echocardiogram (TEE) is mandatory to definitively rule out LAA thrombus prior to cardioversion, accompanied by therapeutic anticoagulation.
• Preferred Anticoagulant: Continuous intravenous unfractionated heparin (UFH) titrated to an aPTT of $50\text{--}70\text{ seconds}$ is strongly preferred over direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) in the ICU due to its short elimination half-life ($60\text{--}90\text{ minutes}$) and immediate reversibility with protamine sulfate if emergency invasive procedures or bleeding events occur.

---

Ventricular Tachycardia (VT) and Ventricular Fibrillation (VF)

Wide-complex tachycardias ($QRS \ge 120\text{ ms}$, rate $> 100\text{ bpm}$) in the ICU represent Ventricular Tachycardia in $> 80\%$ of cases, especially in patients with prior myocardial infarction, coronary artery disease, or structural heart disease. Assuming a wide-complex tachycardia is SVT with aberrancy without proof is a lethal diagnostic error.

Electrocardiographic Clues Favoring VT

• Atrioventricular (AV) Dissociation: Independent atrial (P wave) and ventricular (QRS) rates; pathognomonic for VT.
• Fusion and Capture Beats (Dressler Beats): Rare supraventricular impulses that conduct through the AV node and capture the ventricles either partially (fusion) or fully (capture) during wide-complex tachycardia.
• Extreme Axis Deviation ("Northwest Axis"): Frontal plane QRS axis between $-90^\circ$ and $\pm 180^\circ$ (negative in leads I and aVF, positive in aVR).
• Precordial Concordance: Entire precordial lead set ($V_1\text{ to }V_6$) showing entirely positive or entirely negative QRS complexes without RS complexes.
• QRS Width: Exceeding $140\text{ ms}$ with right bundle branch block (RBBB) morphology, or exceeding $160\text{ ms}$ with left bundle branch block (LBBB) morphology.

Monomorphic Ventricular Tachycardia Management

Monomorphic VT features a single, stable QRS morphology, originating from a fixed anatomical myocardial scar or re-entrant circuit:

• Pulseless VT: High-energy unsynchronized defibrillation ($120\text{--}200\text{ J}$ biphasic), CPR, and ACLS arrest protocol.
• Unstable VT with Pulse: Immediate synchronized electrical cardioversion ($100\text{ J}$ biphasic).
• Stable Monomorphic VT with Pulse:
  • Intravenous Procainamide: Class Ia sodium channel blocker. Administer $20\text{--}50\text{ mg/min}$ continuous infusion until the arrhythmia is terminated, hypotension ensues, QRS widens by $> 50\%$, or the maximum cumulative dose of $17\text{ mg/kg}$ is reached. In the randomized multicenter PROCAMIO trial, procainamide demonstrated significantly higher acute termination efficacy and fewer adverse cardiac events compared to intravenous amiodarone for stable monomorphic VT.
  • Intravenous Amiodarone: $150\text{ mg}$ IV infused over 10 minutes, repeated as necessary for recurrent VT, followed by $1.0\text{ mg/min}$ maintenance infusion.
  • Intravenous Lidocaine: Class Ib antiarrhythmic ($1.0\text{--}1.5\text{ mg/kg}$ IV bolus, followed by $1\text{--}4\text{ mg/min}$ infusion). Highly effective for VT occurring in the setting of acute myocardial ischemia or infarction.

---

Polymorphic VT and Torsades de Pointes (TdP)

Polymorphic ventricular tachycardia is characterized by continuously shifting QRS morphology, amplitude, and electrical axis twisting around the isoelectric line at rates of $200\text{--}250\text{ bpm}$.

                     POLYMORPHIC VT DIFFERENTIATION
                                    │
         ┌──────────────────────────┴──────────────────────────┐
         ▼                                                     ▼
  NORMAL BASELINE QTc (< 450 ms)               PROLONGED BASELINE QTc (> 500 ms)
  "Ischemia-Driven Polymorphic VT"              "TORSADES DE POINTES (TdP)"
  • Etiology: Acute plaque rupture,           • Etiology: Drug-induced, hypokalemia,
    severe coronary hypoperfusion               hypomagnesemia, severe bradycardia
  • Mechanism: Re-entry in ischemic tissue    • Mechanism: Early afterdepolarizations (EADs)
  • Treatment: Immediate reperfusion,         • Treatment: IV Magnesium Sulfate (2 g),
    IV Beta-blockers, IV Lidocaine,             Overdrive pacing (90-110 bpm), Isoproterenol
    Defibrillation for arrest                 • CONTRAINDICATED: Amiodarone, Procainamide

Pathophysiological Distinction: Ischemia vs. Torsades de Pointes

The fundamental clinical imperative is evaluating the baseline corrected QT interval (QTc):

1. Polymorphic VT with Normal Baseline QTc: Driven by acute myocardial ischemia or acute coronary occlusion. Repolarization duration is normal, but acute regional ischemic heterogeneity produces re-entry. Management centers on immediate coronary revascularization (primary PCI), intravenous beta-blockers, intravenous lidocaine, and defibrillation.
2. Polymorphic VT with Prolonged Baseline QTc ($> 500\text{ ms}$): This is Torsades de Pointes (TdP). Prolongation of phase 2 and phase 3 of the cardiac action potential allows reactivation of L-type calcium channels and sodium channels, generating early afterdepolarizations (EADs) during late repolarization. When an EAD reaches threshold potential, it triggers a premature ventricular contraction that falls on the prolonged T-wave, initiating self-sustaining twisting ventricular tachycardia.

Etiologies of Prolonged QTc and Torsades de Pointes in the ICU

• Electrolyte Abnormalities: Severe hypokalemia ($K^+ < 4.0\text{ mEq/L}$), severe hypomagnesemia ($Mg^{2+} < 2.0\text{ mg/dL}$), and severe hypocalcemia.
• QT-Prolonging Pharmacotherapy:
  • Antiarrhythmics: Class Ia (procainamide, quinidine, disopyramide), Class III (sotalol, dofetilide, ibutilide). (Note: Intravenous amiodarone prolongs the QTc significantly, but possesses a very low incidence of TdP due to uniform prolongation of repolarization and calcium channel blockade).
  • Psychotropic Agents: Haloperidol (especially intravenous), chlorpromazine, quetiapine, ziprasidone, citalopram, escitalopram.
  • Antimicrobials: Macrolides (azithromycin, erythromycin), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), azole antifungals (fluconazole, voriconazole).
  • Antiemetics: Ondansetron, droperidol, metoclopramide.
  • Others: Methadone, pentamidine, organophosphate poisoning.
• Severe Bradycardia / High-Grade AV Block: Produces pause-dependent prolongation of repolarization, predisposing to characteristic "short-long-short" sequences that initiate TdP.

Emergent Management Protocol for Torsades de Pointes

1. Intravenous Magnesium Sulfate: First-line pharmacological therapy regardless of baseline serum magnesium concentration. Administer $2\text{ g}$ IV diluted in $50\text{--}100\text{ mL}$ $D_5W$ over about 5 to 15 minutes when a pulse is present; a faster push is reserved for pulseless torsades. If paroxysms recur, repeat with a second $2\text{ g}$ IV bolus 5 to 10 minutes later, followed by a continuous infusion of $2\text{--}4\text{ mg/min}$. Magnesium suppresses EADs by blocking inward L-type calcium current.
2. Discontinue All QT-Prolonging Pharmacotherapy: Immediately halt all offending neuroleptics, antiemetics, antibiotics, and antiarrhythmics.
3. Accelerate Heart Rate to Shorten the QTc Interval:
   • Temporary Transvenous Overdrive Pacing: The most definitive and reliable therapy for recurrent, refractory TdP. Pacing at $90\text{--}110\text{ bpm}$ shortens phase 3 ventricular repolarization, eliminates pause-dependent triggers, and abolishes EADs.
   • Intravenous Isoproterenol Infusion: Pure $\beta$-adrenergic agonist ($2\text{--}10\mu\text{g/min}$) titrated to accelerate baseline heart rate $> 90\text{--}100\text{ bpm}$ as a pharmacological bridge when pacing is delayed. Contraindications: Congenital long QT syndrome or active myocardial ischemia.
4. Aggressive Electrolyte Repletion: Rapidly replenish serum potassium to high-normal levels ($4.5\text{--}5.0\text{ mEq/L}$) and serum magnesium to $> 2.5\text{ mg/dL}$.
5. Unstable or Degenerating TdP: Immediate unsynchronized high-energy defibrillation ($120\text{--}200\text{ J}$ biphasic). Synchronization cannot track polymorphic QRS amplitudes and will fail to deliver energy or deliver an inappropriately timed shock.

---

Narrow-Complex and Pre-Excited Tachycardias

Regular Narrow-Complex Tachycardia (AVNRT, AVRT, Atrial Tachycardia)

• Unstable: synchronized cardioversion.
• Stable: try vagal maneuvers first (the modified Valsalva maneuver with passive leg raise works better than standard Valsalva). If that fails, give adenosine $6\text{ mg}$ rapid IV push with a saline flush, then $12\text{ mg}$ if needed. Use a reduced initial dose (about $3\text{ mg}$) through a central line, after heart transplantation, or with dipyridamole or carbamazepine. Theophylline and caffeine blunt the effect.
• Adenosine terminates re-entry that uses the AV node (AVNRT, orthodromic AVRT). In atrial flutter or atrial tachycardia, transient AV block unmasks the atrial activity instead, which is diagnostic.
• If adenosine fails or the rhythm recurs, IV diltiazem, verapamil, or a beta-blocker are next. Avoid nondihydropyridine calcium-channel blockers in decompensated systolic heart failure.

Multifocal Atrial Tachycardia (MAT)

• At least three distinct P-wave morphologies, varying PR intervals, and an irregular rate above $100\text{ bpm}$. It is classically seen with decompensated COPD, hypoxemia, theophylline, and electrolyte disturbance.
• Treat the underlying lung disease, hypoxemia, hypokalemia, and hypomagnesemia. Rate control with diltiazem, verapamil, or a cardioselective beta-blocker can help. Cardioversion and antiarrhythmics are ineffective, because MAT is not re-entrant.

Atrial Flutter

• Typical flutter shows sawtooth inferior-lead flutter waves at about $300\text{ bpm}$, often with 2:1 conduction (a ventricular rate near $150\text{ bpm}$).
• Rate control is harder than in atrial fibrillation. Synchronized cardioversion works at low energy, and catheter ablation of the cavotricuspid isthmus is highly effective. Stroke prevention follows atrial fibrillation rules.

Pre-Excited Atrial Fibrillation (Wolff-Parkinson-White)

• An irregular, very fast, wide-complex rhythm with varying QRS morphology (rates can exceed $250\text{ bpm}$) in a young patient suggests atrial fibrillation conducting down an accessory pathway.
• Avoid AV-nodal blockers: adenosine, beta-blockers, diltiazem, verapamil, digoxin, and IV amiodarone. Blocking the node can favor accessory-pathway conduction and precipitate ventricular fibrillation.
• Unstable: synchronized cardioversion. Stable: IV procainamide (or ibutilide), then refer for accessory-pathway ablation.